GBS Inc. (GBS) News & Overview - Discounting Cash Flows
GBS
GBS Inc.
GBS (NASDAQ)

GBS's Business Model

GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Sector & Industry Healthcare / Medical - Devices
Website https://gbs.inc
CEO (Chief Executive Officer) Harry Simeonidis
Number of Employees
IPO date December 23, 2020

GBS Latest News

Contact
CountryUS
Address708 3rd Avenue
CityNew York City
StateNY
Phone646 828 8258
Zip Code10019
Other Identifiers
CIK0001725430
ISINUS36151G1058
CUSIP
Open0.4808
Previous Close0.4808
Volume9.03 Thou.
Average Volume51.58 Thou.
Day’s Range0.4507 – 0.4854
52 Week Range0.36-2.89
MA (50)0.4706684
MA (200)0.6530561
Market Cap433.6 Thou.
Shares Out.916.3 Thou.
Earnings DateAug 31, 2022
Beta
Last Dividend
EPS
PE

Industry Competitors for GBS

discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us